Novo Nordisk suspended from UK drug trade body for two years over marketing
A UK industry group has barred Novo Nordisk, the maker of semaglutide medicines, for two years over how it marketed its drugs — a UK membership penalty that does not involve US regulators.
Novo Nordisk, the company that makes the semaglutide medicines Ozempic, Wegovy and Rybelsus, has been suspended from the Association of the British Pharmaceutical Industry for two years [1]. The suspension, reported on March 16, 2023, followed marketing practices the association treated as improper inducements to prescribe [1].
The Association of the British Pharmaceutical Industry, or ABPI, is the trade body for drugmakers operating in the United Kingdom. The penalty is a membership sanction, not a regulatory one. It does not withdraw a medicine from the market and does not change which patients can be prescribed it [1].
Two royal colleges ended their corporate partnerships with Novo Nordisk after the suspension [1]. The colleges have not been publicly named, and neither the value nor the terms of those partnerships has been disclosed.
The specific promotional materials or programs at the center of the case have not been described in detail [1]. It has not been reported which ABPI rules Novo Nordisk was found to have breached, whether the company disputed the finding, or whether it issued a statement about the suspension. The association has not disclosed a precise start date for the two-year term beyond the March 2023 announcement.
Why it matters for patients
The action was taken in the United Kingdom by an industry association [1]. It does not involve the US Food and Drug Administration or any other US regulator, and no US regulator or manufacturer has announced any change to semaglutide products as a result of it.
What the case does show is that how GLP-1 drugs are promoted to prescribers is drawing scrutiny. Inducements to prescribe — payments, gifts, hospitality or other benefits offered to influence prescribing decisions — are the category of conduct at issue here [1]. A suspension of this length from a national industry body is an unusual step, which is why it drew attention beyond the UK.
For patients, the practical questions a case like this raises are usually about the information they get from their own clinicians, not about the drug itself. Details of what Novo Nordisk was found to have done, and how the company responded, have not been made public in the reporting of the suspension [1]. Whether the underlying conduct involved any particular semaglutide product has not been reported.
What happens next
The suspension runs for two years from the March 2023 announcement [1]. Whether Novo Nordisk applies to rejoin the association after that period, and on what terms, has not been disclosed. Neither the ABPI nor the two royal colleges involved has announced any further steps, and no date has been given for a review of the decision.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.